The Effects of Once-Daily Saquinavir/Minidose Ritonavir on the Pharmacokinetics of Methadone

Journal of Clinical Pharmacology

Volumn 44, Issue 3, 2004, Pages 293-304

  Shelton, Mark J ^a,f   Cloen, Denise ^a   DiFrancesco, Robin ^a   Berenson, Charles S ^b   Esch, Andrew ^c   De Caprariis, Pascal J ^d   Palic, Branka ^d   Schur, Jane L ^e   Buggé, Christopher J L ^e   Ljungqvist, Anders ^e   Espinosa, Orlando ^e   Hewitt, Ross G ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^c Sister's Health Care System   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e CEDRA Corporation   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

Methadone; Pharmacokinetics; Ritonavir; Saquinavir

Indexed keywords

METHADONE; RITONAVIR; SAQUINAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ENANTIOMER; FEMALE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; NORMAL HUMAN; SEDATION; SIDE EFFECT;

ADULT; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; METHADONE; MIDDLE AGED; NARCOTICS; RITONAVIR; SAQUINAVIR; STEREOISOMERISM; TIME FACTORS;

EID: 10744225852     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003262956     Document Type: Article

References (35)

1. Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, et al: Safety and pharmacokinetics of once-daily regimens of softgel capsule saquinavir plus mini-dose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother 2000;44:2672-2678.
2. Buss N, Snell P, Bock J, Hsu A, et al: Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 2001;52:255-264.
3. Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, et al: Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999;13:213-224.
4. Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S: Activity of ritonavir plus saquinavir-containing regimens in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998;12:F97-F102.
5. Hsu A, Granneman GR, Cao G, et al: Pharmacokinetic interactions between two immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998;63:453-464.
6. Fischl M, Rodriguez A, Scerpella E, Monroig R, Thompson L, Rechtine D: Impact of directly observed therapy on outcomes in HIV clinical trials. Paper presented at the Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000.
7. Flexner C: HIV protease inhibitors. N Engl J Med 1998;338:1281-1292.
8. Gerber JG, Rhodes RJ: Cytochrome P450 2B6 (CYP2B6) metabolizes methadone (M) preferentially and stereospecifically [poster 2.2]. Paper presented at the Abstracts of the 1st International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the Netherlands, March 30-31, 2000.
9. Eap CB, Broly F, Mino A, Hämmig R, Déglon J, Uehlinger C, et al: Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 2001;21:229-234.
10. Hsu A, Granneman GR, Carothers L, Dennis S, Chiu Y-L, Valdes J, et al: Ritonavir does not increase methadone exposure in healthy volunteers [abstract 342]. Paper presented at the Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
11. Iribarne C, Berthou F, Carlhant D, Dreano Y, Picart D, Lohezic F, et al: Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998;26(3):257-260.
12. Olsen GD, Wendel H, Livermore J, Leger R, Lynn RK, Gerber N: Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther 1977;21:147-157.
13. Judson BA, Horns WH, Goldstein A: Side effects of levo-methadone and racemic methadone in a maintenance program. Clin Pharmacol Ther 1976;20:445-449.
14. 1-acid glycoprotein. Clin Pharmacol Ther 1990;47:338-346.
15. Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg D, et al: Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab Dispos 2001;29:299-303.
16. De Castro J, Aguirre C, Rodriguez-Sasiain JM, Gómez E, Garrido M, Calvo R: The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. Biopharmaceut Drug Dispos 1996;17:551-563.
17. Crivat M, Vittecoq D, Kodjo A, et al: Pharmacokinetics of saquinavir and study of intestinal function in HIV patients [abstract A9]. Paper presented at the 37th ICAAC, Toronto, Canada, September 28-October 1, 1997.
18. Stone BM: Pencil and paper tests: sensitivity to psychotropic drugs. Br J Clin Pharmacol 1984;18:15S-20S.
19. Chernik DA, Gillings D, Laine H, Hendler J, Silver J, Davidson A, et al: Validity and reliability of the observer's assessment of alertness/sedation scale: study with intravenous midazolam. J Clin Psychopharmacol 1990;10:244-251.
20. Gossop M: The development of a Short Opiate Withdrawal Scale (SOWS). Addict Behav 1990;15:487-490.
21. O'Connor PG, Fiellin DA: Pharmacologic treatment of heroindependent patients. Ann Intern Med 2000;133:40-54.
22. Cantilena L, McCrea J, Blazes D, Winchell G, Carides A, Royce C, et al: Lack of a pharmacokinetic interaction between indinavir and methadone [abstract PI-174]. Clin Pharmacol Ther 1999;65:135.
23. Hendrix C, Wakeford J, Wire MB, Bigelow G, Cornell E, Christopher J, et al: Pharmacokinetic and pharmacodynamic evaluation of methadone enantiomers following co-administration with amprenavir in opioid-dependent subjects [abstract 1649]. Paper presented at the Abstracts of the 40th ICAAC, San Francisco, September 17-20, 2000.
24. Hsu PH, Lillibridge JH, Maroldo L, Weiss W, Kerr B: Pharmacokinetic and pharmacodynamic interactions between nelfinavir and methadone. Paper presented at the Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000.
25. Kaletra: prescribing information. Chicago: Abbott Laboratories, 2002.
26. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D, et al: Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J AIDS 2001;27:153-160.
27. McCance-Katz EF, Rainey PM, Friedland G, Jatlow P: The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. CID 2003;37:476-482.
28. Abramson FP, Lutz MO: The kinetics of induction by rifampin of alpha 1-acid glycoprotein and antipyrine clearance in the dog. Drug Metab Dispos 1996;14:46-51.
29. Goodwin SD, Renchan CJ, Schooley RT, Pieper J: Effect of HIV infection on alphal-acid glycoprotein concentrations [MoB.1327]. Int Conf AIDS 1996;11:111.
30. Sadler BM, Gillotin C, Stein D: Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agent Chemother 2001;45:30-37.
31. Hsu A, Granneman R, Bertz RJ: Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokin 1998;35:275-291.
32. Van Heeswijk RPG, Cardiello P, Monhaphol T, Manotaya S, Tongtalung M, Ubolyam S, et al: Once daily dosing of 1600 mg saquinavir (Fortovase™) plus 100 mg ritonavir in HIV-1 infected patients: pharmacokinetics and clinical experience: HIV-NAT 001.3 [poster 3.9]. Paper presented at the 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the Netherlands, April 2-4, 2001.
33. Acosta EP, Saag MS, Montaner JSG: Pharmacokinetics and safety of once daily saquinavir soft gel capsules/ritonavir in HIV-infected anti-retroviral naive patients [poster 3.14]. Paper presented at the 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the Netherlands, April 2-4, 2001.
34. Rostami-Hodjegan A, Wolff K, Hay AWM, Raistrick D, Calvert R: Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol 1999; 48:43-52.
35. Schwartz R, Jayaweera D, de Caprariis P, Jahns B, Hill A, Montaner J: Pharmacokinetic evaluation of HIV(+) African Americans and Caucasians on once daily (QD) saquinavir soft gel capsules (SQV) and mini dose ritonavir (rtv) [poster 3.13]. Paper presented at the 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the Netherlands, April 2-4, 2001.